Rare Childhood Cancer: Understanding Congenital Rhabdomyosarcoma
"Two case studies shed light on the challenges and treatment strategies for this rare cancer diagnosed in newborns."
Rhabdomyosarcoma (RMS), a type of soft tissue sarcoma, is uncommon in children, but its occurrence in newborns is even rarer. Existing research indicates that only a small percentage of RMS cases are diagnosed in infants under one year old, making congenital RMS (diagnosed at birth or shortly thereafter) particularly unusual. Due to its rarity, understanding the characteristics, treatment approaches, and outcomes of congenital RMS is crucial.
This article examines two cases of congenital RMS treated at the Bambino Gesù Children's Hospital between 2000 and 2016. These cases provide valuable insights into the different ways this cancer can manifest and how treatment strategies can impact outcomes. By reviewing these cases, along with existing literature, we aim to contribute to a better understanding of this challenging disease.
The cases highlight the two primary types of RMS: embryonal and alveolar. They also underscore the difficulties in managing RMS in newborns and the importance of tailored treatment approaches.
What “Congenital” Means
The National Human Genome Research Institute explains that “congenital” is a traditional term indicating that a disease, disorder, or trait was seen or thought to have originated around pregnancy and birth. Biology Insights defines a congenital condition as a structural, functional, or metabolic abnormality present at or before birth, regardless of its cause or when it was detected. Together, these sources show that “congenital” describes timing or presumed origin rather than a specific cause.
Case Presentations: Two Different Paths
The first case involved a newborn girl presenting with multiple skin and subcutaneous nodules. These lesions, ranging in color from bluish to purple, were found on her head, limbs, and trunk. Further investigation revealed the presence of alveolar RMS (ARMS), confirmed by the detection of a specific PAX3-FOXO1 fusion transcript through Array-CGH analysis. The cancer had spread to her liver, pancreas, lungs, and bones. Despite chemotherapy and a stem cell transplant, the disease progressed to the central nervous system (CNS), leading to a fatal outcome at nine months of age.
- Case 1: Alveolar RMS (ARMS), disseminated disease, fatal outcome due to CNS progression.
- Case 2: Embryonal RMS (ERMS), localized, successful treatment with surgery and chemotherapy.
Unusual Infant Presentations
Recent reports describe unusual presentations of rhabdomyosarcoma in very young patients. A case report discusses neonatal rhabdomyosarcoma and states that treatment typically combines chemotherapy, surgery, and radiation. A review of infants with rhabdomyosarcoma notes that neonates may have distinctive presenting features, including multiple subcutaneous nodules. Another report describes rare embryonal rhabdomyosarcoma presentations in the middle ear of a 3-year-old boy and girl.
Limited Congenital Case Evidence
Evidence about congenital rhabdomyosarcoma remains limited in the cited report. Researchers retrospectively reviewed the medical records of 89 children with rhabdomyosarcoma treated between 2000 and 2016 in their department. Among those 89 children, they identified two congenital cases. This small number highlights how uncommon congenital presentations were in that clinical series.
Implications and Future Directions
The diagnosis of RMS in newborns presents unique challenges. The rarity of the disease, combined with the vulnerability of infants, necessitates careful consideration of treatment strategies. The research underscores the aggressive nature of alveolar RMS in newborns, often leading to CNS progression despite intensive therapy.
Given the propensity for CNS involvement in alveolar RMS, the researchers suggest that CNS prophylaxis could play a role in preventing leptomeningeal dissemination. Additionally, they emphasize the importance of molecular studies for deeper tumor characterization, treatment stratification, and the identification of new therapeutic targets.
Further research is needed to develop specific guidelines for treating RMS in neonates and infants. Collaborative efforts to collect data and analyze outcomes are essential to improve the prognosis for these young patients. Molecular profiling and the development of targeted therapies offer hope for more effective and less toxic treatments in the future.